Simufilam for Alzheimer's Disease
(REFOCUS-ALZ Trial)
Trial Summary
What is the purpose of this trial?
This trial is testing a medication called simufilam to see if it can help people with mild-to-moderate Alzheimer's disease by improving their brain function and slowing down the progression of their symptoms.
Research Team
Jim Kupiec, MD
Principal Investigator
Cassava Sciences
Eligibility Criteria
This trial is for people with mild-to-moderate Alzheimer's who've had consistent Alzheimer's medication doses for 3+ months and haven't smoked in 3+ years. Participants need a study partner to attend screenings.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive simufilam or placebo twice daily for 76 weeks to evaluate safety and efficacy in enhancing cognition and slowing cognitive decline
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Placebo
- Simufilam
Find a Clinic Near You
Who Is Running the Clinical Trial?
Cassava Sciences, Inc.
Lead Sponsor
Premier Research Group plc
Industry Sponsor
John Ratliff
Premier Research Group plc
Chief Executive Officer since 2024
MBA
Dr. Milena Kanova-Petrova
Premier Research Group plc
Chief Medical Officer since 2024
MD